Keywords

• PFI-3
• best price
• Chengdu Henghui Pharm Tec Co. Ltd

Quick Details

• ProName: PFI-3 high quality
• CasNo: 1819363-80-8
• Molecular Formula: C19H19N3O2
• Appearance: yellow powder
• Application: For laboratory use only- not intended ...
• ProductionCapacity: Metric Ton/Day
• Purity: ≥99%
• Storage: room temperature
• LimitNum: 10 Milligram

Superiority

We are a CRO company, and our Research and Development team is consisted of PhDs and Masters in chemistry and pharmacy.

We are committed to protect our customer’s privacy with the highest level of ethical standard. Our dedicated team will follow up on every order and provide instant feedback on the status to our customer.

We stand behind our product by providing a complete QA report. The test data of customer order can be provided upon request.

We make our efforts to offer customer innovative, customized, high-quality service.

Our custom manufacturing encompasses everything from pharmaceutical intermediates to API.

Details

PFI-3 is a selective, potent and cell-permeable SMARCA2/4 bromodomain inhibitor with a K_d of 89 nM. IC50 & Target: Kd: 89 nM (SMARCA2/4). In Vitro: PFI-3 is a potent, cell-permeable probe capable of displacing ectopically expressed, GFP-tagged SMARCA2-bromodomain from chromatin. PFI-3 binds avidly to both SMARCA2 and SMARCA4 bromodomains (BROMOScan K_d's between 55 and 110 nM) consistent with the binding constant (K_d=89 nM) measured by isothermal titration calorimetry. PFI-3 does not phenocopy the growth inhibitory effects of SMARCA2 knockdown in lung cancer. Exposure of embryonic stem cells to PFI-3 leads to deprivation of stemness and deregulates lineage specification. Furthermore, differentiation of trophoblast stem cells in the presence of PFI-3 is markedly enhanced. PFI-3 binds to certain family VIII bromodomains while displaying significant, broader bromodomain family selectivity. The high specificity of PFI-3 for family VIII is achieved through a novel bromodomain binding mode of a phenolic headgroup that leads to the unusual displacement of water molecules that are generally retained by most other bromodomain inhibitors reported to date